Open AccessSpecific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes
Author(s) -
Matthias Schmitt,
E. Harrer,
Andreas Goldwich,
Michael Bäuerle,
Irina Graedner,
Joachim R. Kalden,
Thomas Harrer
Publication year - 2000
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200004140-00004
Subject(s) - ctl* , epitope , virology , resistance mutation , lamivudine , cytotoxic t cell , biology , clone (java method) , cellular immunity , immunology , reverse transcriptase , immune system , virus , antibody , cd8 , genetics , dna , hepatitis b virus , polymerase chain reaction , in vitro , gene
The reverse transcriptase (RT) M184V mutation within the HLA-A2-restricted HIV-1 cytotoxic T lymphocyte (CTL) epitope VL9 (VIYQYMDDL; RT 179-187) not only induces drug escape against lamivudine but also abolished recognition by a CTL clone derived from a long-term non-progressor. To test whether the variant VL9 epitope containing the M184V mutation represents a new CTL epitope, we studied recognition of this epitope in a cohort of HLA-A2-positive HIV-1-infected patients.